Biotron Ltd has released a press release.
Phase 2 Hepatitis C Trial Success
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Biotron
- BIT225 May have a broader role in limiting hiv-1 infection
- Biotron compounds tested for activity against zika virus
- Interim hcv genotype 3 data from BIT225-008 study
- Annual Report to Shareholders
Later from Biotron
- Trading halt
- $1.5 Million R&D Tax Rebate
- Biotron compounds demonstrate activity against Zika virus
- Zika Virus Program Update
- BIT225 Accelerates HIV-1 Virus Reduction
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron